Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 24, 2015, Pages 9421-9437

  Röhrig, Ute F ^a   Majjigapu, Somi Reddy ^a,b   Vogel, Pierre ^b,c   Zoete, Vincent ^a   Michielin, Olivier ^a,c,d  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b EPFL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLIMIDAZOLE; ANTINEOPLASTIC AGENT; ECONAZOLE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE 1 INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

ARTICLE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ASSAY; KINETICS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL SURVIVAL; DRUG DISCOVERY; ENZYME ASSAYS; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KINETICS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN;

EID: 84946425042     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00326     Document Type: Article

References (154)

1. Page, D. B.; Postow, M. A.; Callahan, M. K.; Allison, J. P.; Wolchok, J. D. Immune modulation in cancer with antibodies Annu. Rev. Med. 2014, 65, 185-202
2. Rosenberg, S. A. Raising the bar: the curative potential of human cancer immunotherapy Sci. Transl. Med. 2012, 4, 127ps8
3. Kershaw, M. H.; Westwood, J. A.; Slaney, C. Y.; Darcy, P. K. Clinical application of genetically modified T cells in cancer therapy Clin. Transl. Oncol. 2014, 3, e16
4. Holmgaard, R. B.; Zamarin, D.; Munn, D. H.; Wolchok, J. D.; Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 J. Exp. Med. 2013, 210, 1389-1402
5. Spranger, S.; Koblish, H. K.; Horton, B.; Scherle, P. A.; Newton, R.; Gajewski, T. F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment J. Immunother. Cancer 2014, 2, 3
6. Crunkhorn, S. Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies Nat. Rev. Drug Discovery 2014, 13, 879
7. Stone, T. W.; Stoy, N.; Darlington, L. G. An expanding range of targets for kynurenine metabolites of tryptophan Trends Pharmacol. Sci. 2013, 34, 136-43
8. Munn, D. H.; Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses Trends Immunol. 2013, 34, 137-143
9. Barth, H.; Raghuraman, S. Persistent infectious diseases say-IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy Crit. Rev. Microbiol. 2014, 40, 360-368
10. Platten, M.; Wick, W.; Van den Eynde, B. J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion Cancer Res. 2012, 72, 5435-5440
11. Platten, M.; von Knebel Doeberitz, N.; Oezen, I.; Wick, W.; Ochs, K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors Front. Immunol. 2015, 5, 673
12. van Baren, N.; Van den Eynde, B. J. Tryptophan-degrading enzymes in tumoral immune resistance Front. Immunol. 2015, 6, 34
13. Uyttenhove, C.; Pilotte, L.; Théate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 2003, 9, 1269-1274
14. Prendergast, G. C.; Smith, C.; Thomas, S.; Mandik-Nayak, L.; Laury-Kleintop, L.; Metz, R.; Muller, A. J. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer Cancer Immunol. Immunother. 2014, 63, 721-735
15. Théate, I.; van Baren, N.; Pilotte, L.; Moulin, P.; Larrieu, P.; Renauld, J.-C.; Hervé, C.; Gutierrez-Roelens, I.; Marbaix, E.; Sempoux, C.; Van den Eynde, B. J. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues Cancer Immunol. Res. 2015, 3, 161-172
16. Godin-Ethier, J.; Hanafi, L.-A.; Piccirillo, C. A.; Lapointe, R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives Clin. Cancer Res. 2011, 17, 6985-6991
17. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat. Med. 2005, 11, 312-319
18. Liu, X.; Shin, N.; Koblish, H. K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M. J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K. J.; Polam, P.; Sparks, R. B.; Yue, E. W.; Li, Y.; Wynn, R.; Fridman, J. S.; Burn, T. C.; Combs, A. P.; Newton, R. C.; Scherle, P. A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 2010, 115, 3520-3530
19. Yang, S.; Li, X.; Hu, F.; Li, Y.; Yang, Y.; Yan, J.; Kuang, C.; Yang, Q. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice J. Med. Chem. 2013, 56, 8321-8231
20. Li, M.; Bolduc, A. R.; Hoda, M. N.; Gamble, D. N.; Dolisca, S.-B.; Bolduc, A. K.; Hoang, K.; Ashley, C.; McCall, D.; Rojiani, A. M.; Maria, B. L.; Rixe, O.; MacDonald, T. J.; Heeger, P. S.; Mellor, A. L.; Munn, D. H.; Johnson, T. S. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma J. Immunother. Cancer 2014, 2, 21
21. Opitz, C. A.; Litzenburger, U. M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G. J.; Miller, C. L.; Lutz, C.; Radlwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 2011, 478, 197-203
22. Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolušić, E.; Frédérick, R.; Plaen, E. D.; Uyttenhove, C.; Wouters, J.; Masereel, B.; Van den Eynde, B. J. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 2497-2502
23. Metz, R.; DuHadaway, J. B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A. J.; Prendergast, G. C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan Cancer Res. 2007, 67, 7082-7087
24. Ball, H. J.; Sanchez-Perez, A.; Weiser, S.; Austin, C. J. D.; Astelbauer, F.; Miu, J.; McQuillan, J. A.; Stocker, R.; Jermiin, L. S.; Hunt, N. H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice Gene 2007, 396, 203-213
25. Fatokun, A. A.; Hunt, N. H.; Ball, H. J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease Amino Acids 2013, 45, 1319-1329
26. Metz, R.; Smith, C.; DuHadaway, J. B.; Chandler, P.; Baban, B.; Merlo, L. M. F.; Pigott, E.; Keough, M. P.; Rust, S.; Mellor, A. L.; Mandik-Nayak, L.; Muller, A. J.; Prendergast, G. C. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation Int. Immunol. 2014, 26, 357-367
27. Prendergast, G. C.; Metz, R.; Muller, A. J.; Merlo, L. M. F.; Mandik-Nayak, L. IDO2 in immunomodulation and autoimmune disease Front. Immunol. 2014, 5, 585
28. Ball, H. J.; Jusof, F. F.; Bakmiwewa, S. M.; Hunt, N. H.; Yuasa, H. J. Tryptophan-catabolizing enzymes-party of three Front. Immunol. 2014, 5, 485
29. 2 incorporation by a heme-containing dioxygenase Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 2611-2616
30. Tojo, S.; Kohno, T.; Tanaka, T.; Kamioka, S.; Ota, Y.; Ishii, T.; Kamimoto, K.; Asano, S.; Isobe, Y. Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors ACS Med. Chem. Lett. 2014, 5, 1119-1123
31. Röhrig, U. F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A. J. G.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational design of indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 2010, 53, 1172-1189
32. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 2009, 52, 7364-7367
33. Koblish, H. K.; Hansbury, M. J.; Bowman, K. J.; Yang, G.; Neilan, C. L.; Haley, P. J.; Burn, T. C.; Waeltz, P.; Sparks, R. B.; Yue, E. W.; Combs, A. P.; Scherle, P. A.; Vaddi, K.; Fridman, J. S. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors Mol. Cancer Ther. 2010, 9, 489-498
34. Mautino, M. R.; Jaipuri, F. A.; Waldo, J.; Kumar, S.; Adams, J.; van Allen, C.; Marcinowicz-Flick, A.; Munn, D.; Vahanian, N. N.; Link, C. J. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy [abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, Apr 6-10, 2013; Cancer Research: Philadelphia, PA, 2013.
35. Nayak, A.; Hao, Z.; Sadek, R.; Vahanian, N.; Ramsey, W.; Kennedy, E.; Mautino, M.; Link, C.; Bourbo, P.; Dobbins, R.; Adams, K.; Diamond, A.; Marshall, L.; Munn, D. H.; Janik, J.; Khleif, S. N. A phase I study of NLG919 for adult patients with recurrent advanced solid tumors J. Immunother. Cancer 2014, 2, P250
36. Cady, S. G.; Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase Arch. Biochem. Biophys. 1991, 291, 326-333
37. Löb, S.; Königsrainer, A.; Rammensee, H.-G.; Opelz, G.; Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? Nat. Rev. Cancer 2009, 9, 445-452
38. Qian, F.; Villella, J.; Wallace, P. K.; Mhawech-Fauceglia, P.; Tario, J. D.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P. J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L. J.; Odunsi, K. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer Chem. Rev. 2009, 69, 5498-5504
39. Opitz, C. A.; Litzenburger, U. M.; Opitz, U.; Sahm, F.; Ochs, K.; Lutz, C.; Wick, W.; Platten, M. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells PLoS one 2011, 6, e19823
40. Metz, R.; Rust, S.; DuHadaway, J. B.; Mautino, M. R.; Munn, D. H.; Vahanian, N. N.; Link, C. J.; Prendergast, G. C. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan Oncoimmunology 2012, 1, 1460-1468
41. Sheridan, C. IDO inhibitors move center stage in immuno-oncology Nat. Biotechnol. 2015, 33, 321-322
42. Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L. P.; Borges, L.; McCarter, J. D.; Sutherland, C. L. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors Biochim. Biophys. Acta 2011, 1814, 1947-1954
43. Balog, J.; Huang, A.; Chen, B.; Chen, L.; Shan, W. IDO inhibitors. Patent WO2014/150646, 2014.
44. Balog, J.; Huang, A.; Chen, B.; Chen, L.; Seitz, S.; Hart, A.; Markwalder, J. Inhibitors of indoleamine 2,3-dioxygenase (IDO). Patent WO2014/150677, 2014.
45. Markwalder, J.; Seitz, S.; Balog, J.; Huang, A.; Mandal, S.; Williams, D.; Hart, A.; Inghrim, J. IDO inhibitors. Patent WO2015/002918, 2015.
46. Markwalder, J.; Balog, J.; Huang, A.; Seitz, S. IDO inhibitors. Patent WO2015/006520, 2015.
47. Banerjee, M.; Middya, S.; Shrivastava, R.; Raina, S.; Surya, A.; Yadav, V. K.; Kapoor, K. K. Aminonitriles as kynurenine pathway inhibitors. Patent WO2014/141110, 2014.
48. Banerjee, M.; Middya, S.; Shrivastava, R.; Raina, S.; Surya, A.; Yadav, D. B.; Yadav, V. K.; Kapoor, K. K.; Venkatesan, A.; Smith, R. A.; Thompson, S. K. Inhibitors of the kynurenine pathway. Patent WO2014/186035, 2014.
49. http://iometpharma.com/research/pipeline (accessed April, 2015).
50. http://www.iteostherapeutics.com/pipeline (accessed April 2015).
51. Boyall, D.; Davis, C.; Dodd, J.; Everitt, S.; Miller, A.; Weber, P.; Westcott, J.; Young, S. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase. Patent WO2014/081689, 2014.
52. Baell, J.; Walters, M. A. Chemical con artists foil drug discovery Nature 2014, 513, 8-10
53. Takikawa, O.; Kuroiwa, T.; Yamazaki, F.; Kido, R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity J. Biol. Chem. 1988, 263, 2041-2048
54. Vottero, E.; Mitchell, D. A.; Page, M. J.; MacGillivray, R. T. A.; Sadowski, I. J.; Roberge, M.; Mauk, A. G. Cytochrome b(5) is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast FEBS Lett. 2006, 580, 2265-2268
55. Maghzal, G. J.; Thomas, S. R.; Hunt, N. H.; Stocker, R. Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells J. Biol. Chem. 2008, 283, 12014-12025
56. Pearson, J. T.; Siu, S.; Meininger, D. P.; Wienkers, L. C.; Rock, D. A. In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b(5) and methylene blue Biochemistry 2010, 49, 2647-2656
57. Yamamoto, S.; Hayaishi, O. Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes J. Biol. Chem. 1967, 242, 5260-5266
58. Ohnishi, T.; Hirata, F.; Hayaish, O. Indoleamine 2,3-dioxygenase. Potassium superoxide as substrate J. Biol. Chem. 1977, 252, 4643-4647
59. Kumar, S.; Malachowski, W.; DuHadaway, J.; Lalonde, J.; Carroll, P.; Jaller, D.; Metz, R.; Prendergast, G.; Muller, A. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors J. Med. Chem. 2008, 51, 1706-1718
60. Wardman, P. Reduction potentials of one-electron couples involving free radicals in aqueous solution J. Phys. Chem. Ref. Data 1989, 18, 1637
61. Röhrig, U. F.; Majjigapu, S. R.; Chambon, M.; Bron, S.; Pilotte, L.; Colau, D.; Van den Eynde, B. J.; Turcatti, G.; Vogel, P.; Zoete, V.; Michielin, O. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors Eur. J. Med. Chem. 2014, 84, 284-301
62. Rana, P.; Naven, R.; Narayanan, A.; Will, Y.; Jones, L. H. Chemical motifs that redox cycle and their associated toxicity MedChemComm 2013, 4, 1175
63. Blois, M. S. Antioxidant determinations by the use of a stable free radical Nature 1958, 181, 1199-1200
64. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 2003, 46, 4477-4486
65. Shoichet, B. K. Screening in a spirit haunted world Drug Discovery Today 2006, 11, 607-615
66. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery J. Med. Chem. 2006, 49, 7274-7277
67. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L.; Ramsden, N. Strategic pooling of compounds for high-throughput screening J. Chem. Inf. Comput. Sci. 1999, 39, 897-902
68. Blake, J. F. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate Med. Chem. 2005, 1, 649-655
69. Huth, J. R.; Mendoza, R.; Olejniczak, E. T.; Johnson, R. W.; Cothron, D. A.; Liu, Y.; Lerner, C. G.; Chen, J.; Hajduk, P. J. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens J. Am. Chem. Soc. 2005, 127, 217-224
70. Baell, J. B.; Holloway, G. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2140
71. Bruns, R. F.; Watson, I. Rules for identifying potentially reactive or promiscuous compounds J. Med. Chem. 2012, 55, 9763-9772
72. Cumming, J. G.; Davis, A. M.; Muresan, S.; Haeberlein, M.; Chen, H. Chemical predictive modelling to improve compound quality Nat. Rev. Drug Discovery 2013, 12, 948-962
73. Terentis, A. C.; Freewan, M.; Sempértegui Plaza, T. S.; Raftery, M. J.; Stocker, R.; Thomas, S. R. The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues Biochemistry 2010, 49, 591-600
74. McCallum, M. M.; Nandhikonda, P.; Temmer, J. J.; Eyermann, C.; Simeonov, A.; Jadhav, A.; Yasgar, A.; Maloney, D.; Arnold, A. L. High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe J. Biomol. Screening 2013, 18, 705-713
75. Dahlin, J. L.; Nissink, J. W. M.; Strasser, J. M.; Francis, S.; Higgins, L.; Zhou, H.; Zhang, Z.; Walters, M. A. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS J. Med. Chem. 2015, 58, 2091-2113
76. Feng, B. Y.; Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors Nat. Protoc. 2006, 1, 550-553
77. Alegre, E.; López, A. S.; González, A. Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine Anal. Biochem. 2005, 339, 188-189
78. Matin, A.; Streete, I. M.; Jamie, I. M.; Truscott, R. J. W.; Jamie, J. F. A fluorescence-based assay for indoleamine 2,3-dioxygenase Anal. Biochem. 2006, 349, 96-102
79. Tomek, P.; Palmer, B. D.; Flanagan, J. U.; Fung, S.-P. S.; Bridewell, D. J. A.; Jamie, J. F.; Ching, L.-M. Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity Anal. Bioanal. Chem. 2013, 405, 2515-2524
80. Klockow, J. L.; Glass, T. E. Development of a fluorescent chemosensor for the detection of kynurenine Org. Lett. 2013, 15, 235-237
81. Seegers, N.; van Doornmalen, A. M.; Uitdehaag, J. C. M.; de Man, J.; Buijsman, R. C.; Zaman, G. J. R. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes J. Biomol. Screening 2014, 19, 1266-1274
82. Lu, C.; Lin, Y.; Yeh, S.-R. Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase J. Am. Chem. Soc. 2009, 131, 12866-12867
83. Nickel, E.; Nienhaus, K.; Lu, C.; Yeh, S.-R.; Nienhaus, G. U. Ligand and substrate migration in human indoleamine 2,3-dioxygenase J. Biol. Chem. 2009, 284, 31548-31554
84. Lu, C.; Lin, Y.; Yeh, S.-R. Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase Biochemistry 2010, 49, 5028-5034
85. Nienhaus, K.; Nickel, E.; Lu, C.; Yeh, S.-R.; Nienhaus, G. U. Ligand migration in human indoleamine-2,3 dioxygenase IUBMB Life 2011, 63, 153-159
86. Efimov, I.; Basran, J.; Sun, X.; Chauhan, N.; Chapman, S. K.; Mowat, C. G.; Raven, E. L. The mechanism of substrate inhibition in human indoleamine 2,3-dioxygenase J. Am. Chem. Soc. 2012, 134, 3034-3041
87. Weber, B.; Nickel, E.; Horn, M.; Nienhaus, K.; Nienhaus, G. U. Substrate inhibition in human indoleamine 2,3-dioxygenase J. Phys. Chem. Lett. 2014, 5, 756-761
88. Peterson, A. C.; Migawa, M. T.; Martin, M. J.; Hamaker, L. K.; Czerwinski, K. M.; Zhang, W.; Arend, R. A.; Fisette, P. L.; Okazi, Y.; Will, J. A.; Brown, R. R.; Cook, J. M. Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase Med. Chem. Res. 1994, 3, 531-544
89. Hou, D.-Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res. 2007, 67, 792-801
90. Nakashima, H.; Uto, Y.; Nakata, E.; Nagasawa, H.; Ikkyu, K.; Hiraoka, N.; Nakashima, K.; Sasaki, Y.; Sugimoto, H.; Shiro, Y.; Hashimoto, T.; Okamoto, Y.; Asakawa, Y.; Hori, H. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors Bioorg. Med. Chem. 2008, 16, 8661-8669
91. Yu, C.-J.; Zheng, M.-F.; Kuang, C.-X.; Huang, W.-D.; Yang, Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2,3-dioxygenase activity in vitro J. Alzheimer's Dis. 2010, 22, 257-266
92. Sono, M.; Cady, S. G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands Biochemistry 1989, 28, 5392-5399
93. Dolušić, E.; Larrieu, P.; Blanc, S.; Sapunaric, F.; Pouyez, J.; Moineaux, L.; Colette, D.; Stroobant, V.; Pilotte, L.; Colau, D.; Ferain, T.; Fraser, G.; Galleni, M.; Frère, J.-M.; Masereel, B.; Van den Eynde, B.; Wouters, J.; Frédérick, R. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors Eur. J. Med. Chem. 2011, 46, 3058-3065
94. Röhrig, U. F.; Majjigapu, S. R.; Grosdidier, A.; Bron, S.; Stroobant, V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition J. Med. Chem. 2012, 55, 5270-5290
95. Thomas, S. R.; Salahifar, H.; Mashima, R.; Hunt, N. H.; Richardson, D. R.; Stocker, R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate J. Immunol. 2001, 166, 6332-6340
96. Bakmiwewa, S. M.; Fatokun, A.; Tran, A.; Payne, R. J.; Hunt, N. H.; Ball, H. J. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2 Bioorg. Med. Chem. Lett. 2012, 22, 7641-7646
97. Cerejo, M.; Andrade, G.; Roca, C.; Sousa, J.; Rodrigues, C.; Pinheiro, R.; Chatterjee, S.; Vieira, H.; Calado, P. A powerful yeast-based screening assay for the identification of inhibitors of indoleamine 2,3-dioxygenase J. Biomol. Screening 2012, 17, 1362-1371
98. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase J. Med. Chem. 2008, 51, 4968-4977
99. Flick, H. E.; Lalonde, J. M.; Malachowski, W. P.; Muller, A. J. The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1 Int. J. Tryptophan Res. 2013, 6, 35-45
100. Röhrig, U. F.; Grosdidier, A.; Zoete, V.; Michielin, O. Docking to heme proteins J. Comput. Chem. 2009, 30, 2305-2315
101. Kirton, S. B.; Murray, C. W.; Verdonk, M. L.; Taylor, R. D. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins Proteins 2005, 58, 836-844
102. Fung, S.-P. S.; Wang, H.; Tomek, P.; Squire, C. J.; Flanagan, J. U.; Palmer, B. D.; Bridewell, D. J.; Tijono, S. M.; Jamie, J. F.; Ching, L.-M. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1) Bioorg. Med. Chem. 2013, 21, 7595-7603
103. Serra, S.; Moineaux, L.; Vancraeynest, C.; Masereel, B.; Wouters, J.; Pochet, L.; Frédérick, R. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties Eur. J. Med. Chem. 2014, 82, 96-105
104. Huang, Q.; Zheng, M.; Yang, S.; Kuang, C.; Yu, C.; Yang, Q. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors Eur. J. Med. Chem. 2011, 46, 5680-5687
105. Friberg, M.; Jennings, R.; Alsarraj, M.; Dessureault, S.; Cantor, A.; Extermann, M.; Mellor, A. L.; Munn, D. H.; Antonia, S. J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection Int. J. Cancer 2002, 101, 151-155
106. Muller, A. J.; Malachowski, W. P.; Prendergast, G. C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors Expert Opin. Ther. Targets 2005, 9, 831-849
107. Watanabe, Y.; Fujiwara, M.; Hayaishi, O. 2,5-Dihydro-L-phenylalanine: a competitive inhibitor of indoleamine 2,3-dioxygenase Biochem. Biophys. Res. Commun. 1978, 85, 273-279
108. Saito, K.; Chen, C. Y.; Masana, M.; Crowley, J. S.; Markey, S. P.; Heyes, M. P. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells) Biochem. J. 1993, 291, 11-14
109. Sono, M.; Roach, M.; Coulter, E.; Dawson, J. Heme-containing oxygenases Chem. Rev. 1996, 96, 2841-2888
110. Southan, M.; Truscott, R.; Jamie, J.; Pelosi, L.; Walker, M.; Maeda, H.; Iwamoto, Y.; Toné, S. Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase Med. Chem. Res. 1996, 6, 343-352
111. Eguchi, N.; Watanabe, Y.; Kawanishi, K.; Hashimoto, Y.; Hayaishi, O. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives Arch. Biochem. Biophys. 1984, 232, 602-609
112. Peterson, A. C.; Loggia, A. J. L.; Hamaker, L. K.; Arend, R. A.; Fisette, P. L.; Okazi, Y.; Will, J. A.; Brown, R. R.; Cook, J. M. Evaluation of substituted β-carbolines as noncompetitive indoleamine 2,3-dioxygenase inhibitors Med. Chem. Res. 1993, 3, 473-482
113. Brastianos, H. C.; Vottero, E.; Patrick, B. O.; Soest, R. V.; Matainaho, T.; Mauk, A. G.; Andersen, R. J. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua J. Am. Chem. Soc. 2006, 128, 16046-16047
114. Gaspari, P.; Banerjee, T.; Malachowski, W. P.; Muller, A. J.; Prendergast, G. C.; DuHadaway, J.; Bennett, S.; Donovan, A. M. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 2006, 49, 684-692
115. Pereira, A.; Vottero, E.; Roberge, M.; Mauk, A. G.; Andersen, R. J. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific marine hydroid Garveia annulata J. Nat. Prod. 2006, 69, 1496-1499
116. Carr, G.; Chung, M. K. W.; Mauk, A. G.; Andersen, R. J. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A J. Med. Chem. 2008, 51, 2634-2637
117. Carr, G.; Tay, W.; Bottriell, H.; Andersen, S. K.; Mauk, A. G.; Andersen, R. J. Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina Org. Lett. 2009, 11, 2996-2999
118. Jang, J.-P.; Jang, J.-H.; Soung, N.-K.; Kim, H.-M.; Jeong, S.-J.; Asami, Y.; Shin, K.-S.; Kim, M. R.; Oh, H.; Kim, B. Y.; Ahn, J. S. Benzomalvin E, an indoleamine 2,3-dioxygenase inhibitor isolated from Penicillium sp. FN070315 J. Antibiot. 2012, 65, 215-217
119. Williams, D. E.; Steinø, A.; de Voogd, N. J.; Mauk, a. G.; Andersen, R. J. Halicloic acids A and B isolated from the marine sponge Haliclona sp. collected in the Philippines inhibit indoleamine 2,3-dioxygenase J. Nat. Prod. 2012, 75, 1451-1458
120. Bridewell, D. J.; Sperry, J.; Smith, J. R.; Kosim-Satyaputra, P.; Ching, L.-M.; Jamie, J. F.; Brimble, M. Natural product-inspired pyranonaphthoquinone inhibitors of indoleamine 2,3-dioxygenase-1 (IDO-1) Aust. J. Chem. 2013, 66, 40-49
121. Dolušić, E.; Larrieu, P.; Meinguet, C.; Colette, D.; Rives, A.; Blanc, S.; Ferain, T.; Pilotte, L.; Stroobant, V.; Wouters, J.; Van den Eynde, B.; Masereel, B.; Delfourne, E.; Frédérick, R. Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A Bioorg. Med. Chem. Lett. 2013, 23, 47-54
122. Jang, J.-P.; Jang, J.-H.; Oh, M.; Son, S.; Kim, S. M.; Kim, H.-M.; Shin, K.-S.; Oh, H.; Soung, N. K.; Hong, Y.-S.; Kim, B. Y.; Ahn, J. S. Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058 J. Antibiot. 2013, 67, 331-333
123. Pasceri, R.; Siegel, D.; Ross, D.; Moody, C. J. Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A J. Med. Chem. 2013, 56, 3310-3317
124. Carvalho, C.; Siegel, D.; Inman, M.; Xiong, R.; Ross, D.; Moody, C. J. Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation Org. Biomol. Chem. 2014, 12, 2663-2674
125. Centko, R. M.; Steinø, A.; Rosell, F. I.; Patrick, B. O.; de Voogd, N.; Mauk, A. G.; Andersen, R. J. Indoleamine 2,3-dioxygenase inhibitors isolated from the sponge Xestospongia vansoesti: structure elucidation, analogue synthesis, and biological activity Org. Lett. 2014, 16, 6480-6483
126. Yamamoto, R.; Yamamoto, Y.; Imai, S.; Fukutomi, R.; Ozawa, Y.; Abe, M.; Matuo, Y.; Saito, K. Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme PLoS one 2014, 9, e88789
127. Mautino, M.; Jaipuri, F.; Marcinowicz-Flick, A.; Kesharwani, T.; Waldo, J. IDO inhibitors. Patent WO2009/073620, 2009.
128. Dolušić, E.; Larrieu, P.; Blanc, S.; Sapunaric, F.; Norberg, B.; Moineaux, L.; Colette, D.; Stroobant, V.; Pilotte, L.; Colau, D.; Ferain, T.; Fraser, G.; Galleni, M.; Galeni, M.; Frère, J.-M.; Masereel, B.; Van den Eynde, B.; Wouters, J.; Frédérick, R. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors Bioorg. Med. Chem. 2011, 19, 1550-1561
129. Smith, J. R.; Evans, K. J.; Wright, A.; Willows, R. D.; Jamie, J. F.; Griffith, R. Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen Bioorg. Med. Chem. 2012, 20, 1354-1363
130. Matsuno, K.; Yamazaki, H.; Isaka, Y.; Takai, K.; Unno, Y.; Ogo, N.; Ishikawa, Y.; Fujii, S.; Takikawa, O.; Asai, A. Novel candesartan derivatives as indoleamine 2,3-dioxygenase inhibitors Med. Chem. Commun. 2012, 3, 475
131. Cheng, M.-F.; Hung, M.-S.; Song, J.-S.; Lin, S.-Y.; Liao, F.-Y.; Wu, M.-H.; Hsiao, W.; Hsieh, C.-L.; Wu, J.-S.; Chao, Y.-S.; Shih, C.; Wu, S.-Y.; Ueng, S.-H. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 3403-3406
132. Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R. J.; Mauk, A. G.; Roberge, M. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast Biotechnol. J. 2006, 1, 282-288
133. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
134. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G. D.; Mitchison, T. J.; Moskowitz, M. A.; Yuan, J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat. Chem. Biol. 2005, 1, 112-119
135. Vandenabeele, P.; Grootjans, S.; Callewaert, N.; Takahashi, N. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models Cell Death Differ. 2013, 20, 185-187
136. Tanaka, M.; Li, X.; Hikawa, H.; Suzuki, T.; Tsutsumi, K.; Sato, M.; Takikawa, O.; Suzuki, H.; Yokoyama, Y. Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors Bioorg. Med. Chem. 2013, 21, 1159-1165
137. Cavalheiro Tourino, M.; de Oliveira, E. M.; Bellé, L. P.; Knebel, F. H.; Albuquerque, R. C.; Dörr, F. A.; Okada, S. S.; Migliorini, S.; Soares, I. S.; Campa, A. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells Cell Biochem. Funct. 2013, 31, 361-364
138. Chauhan, N.; Basran, J.; Rafice, S. A.; Efimov, I.; Millett, E. S.; Mowat, C. G.; Moody, P. C. E.; Handa, S.; Raven, E. L. How is the distal pocket of a heme protein optimized for binding of tryptophan? FEBS J. 2012, 279, 4501-4509
139. Andersen, R.; Pereira, A.; Huang, X.-H.; Mauk, G.; Vottero, E.; Roberge, M.; Balgi, A. Indoleamine 2,3-dioxygenase (IDO) inhibitors. Patent WO2006/005185, 2006.
140. Andersen, R.; Leblanc, M.; Brastianos, H.; Vottero, E.; Roberge, M.; Mauk, G.; Carr, G. Substituted quinone indoleamine 2,3-dioxygenase (IDO) inhibitors and synthesis and uses thereof. Patent WO2008/052352, 2008.
141. Pantouris, G.; Mowat, C. G. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase Biochem. Biophys. Res. Commun. 2014, 443, 28-31
142. Austin, C. J. D.; Kahlert, J.; Issa, F.; Reed, J. H.; Smith, J. R.; Ioppolo, J. A.; Ong, J. A.; Jamie, J. F.; Hibbs, D.; Rendina, L. M. The first indoleamine-2,3-dioxygenase-1 (IDO1) inhibitors containing carborane Dalton Trans. 2014, 1, 3-8
143. Suwa, S.; Kasubata, A.; Kato, M.; Iida, M.; Watanabe, K.; Miura, O.; Fukuda, T. The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies Int. J. Oncol. 2015, 46, 1369-1376
144. Frieden, E.; Westmark, G. W.; Schor, J. M. Inhibition of tryptophan pyrrolase by serotonin, epinephrine and tryptophan analogs Arch. Biochem. Biophys. 1961, 92, 176-182
145. Bittner, S. When quinones meet amino acids: chemical, physical and biological consequences Amino Acids 2006, 30, 205-224
146. Matsuno, K.; Takai, K.; Isaka, Y.; Unno, Y.; Sato, M.; Takikawa, O.; Asai, A. S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase Bioorg. Med. Chem. Lett. 2010, 20, 5126-5129
147. Mautino, M.; Kumar, S.; Jaipuri, F.; Waldo, J.; Kesharwani, T.; Zhang, X. Imidazole derivatives as IDO inhibitors. Patent WO2011/056652, 2011.
148. Mautino, M.; Kumar, S.; Waldo, J.; Jaipuri, F.; Kesharwani, T. Fused imidazole derivatives useful as IDO inhibitors. Patent WO2012/142237, 2012.
149. Kumar, S.; Waldo, J.; Jaipuri, F.; Mautino, M. Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization. Patent WO2014/159248, 2014.
150. Combs, A.; Zhu, W.; Sparks, R. B. N-Hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. Patent WO2008/058178, 2008.
151. Combs, A.; Yue, E.; Sparks, R.; Zhu, W.; Zhou, J.; Lin, Q.; Weng, L.; Yue, T.; Liu, P. 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. Patent WO2010/005958, 2010.
152. Liu, X.; Shin, N.; Koblish, H. K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M. J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K. J.; Polam, P.; Sparks, R. B.; Yue, E. W.; Li, Y.; Wynn, R.; Fridman, J. S.; Burn, T. C.; Combs, A. P.; Newton, R. C.; Scherle, P. A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 2010, 115, 3520-3530
153. http://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle (accessed April 2015).
154. Pettersen, E. F.; Goddard, T.; Huang, C.; Couch, G.; Greenblatt, D.; Meng, E.; Ferrin, T. E. UCSF Chimera-A visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612